afamelanotide (melanotan i) mastery course
Unit 1 of 12 -- free

From Melanotan I to Afamelanotide

The evidence-backed MC1R and EPP story behind one of the most misunderstood peptide names on the internet

This Is Not a Generic Tanning-Peptide Course

“Melanotan I” is the kind of name that makes peptide education harder than it needs to be. In modern medical use, the meaningful identity is afamelanotide, marketed as SCENESSE, with a specific evidence-backed role in erythropoietic protoporphyria (EPP).

This course starts by clearing up the naming confusion, then rebuilds the topic from the real pillars: MC1R biology, eumelanin signaling, EPP light toxicity, clinical trials, safety monitoring, regulation, and the distinction from Melanotan II.


From Alpha-MSH to Afamelanotide

The molecule makes more sense when you start with the endogenous hormone lineage.

Afamelanotide comes out of the alpha-melanocyte-stimulating hormone lineage, which is why the course centers receptor biology instead of internet folklore. Older naming conventions such as “Melanotan I” still show up online, but the clinical evidence lives under the afamelanotide / SCENESSE identity.

That naming split matters. One framing leads to a discussion about approved photoprotection in EPP; the other often drifts into gray-market tanning talk. This course keeps those paths separate.


The Alpha-MSH Lineage

MC1R signaling and eumelanin matter more here than the buzzword “tanning.”

interactive mc1r map

Why EPP Is the Real Clinical Story

The strongest evidence is about pain-free light exposure, not casual cosmetic use.

In EPP, visible-light exposure can trigger severe phototoxic pain. That changes the meaning of “more light tolerance” from a cosmetic concept into a functional clinical outcome. Afamelanotide is taught here through that lens.

Once you understand EPP, the pivotal trial endpoints stop looking vague. They become direct measures of day-to-day function in a disease where daylight itself can be disabling.


Why This Is Not a Tanning Course

The gray market collapsed multiple melanocortin stories into one. That is exactly what this course fixes.

important context: afamelanotide should not be taught as a sunscreen replacement, a cosmetic free-for-all, or a synonym for Melanotan II. Those shortcuts break the evidence base.

What You Will Learn

The rest of the course moves from receptor biology into disease context, trials, monitoring, regulation, and family-tree distinctions.

MC1R
core receptor target
EPP
core clinical use case
12
units including final exam
Evidence-first
not gray-market folklore

Knowledge Check

Confirm the naming, receptor, and disease-context fundamentals before moving deeper.


Practice

Reinforce the distinctions that matter most for the rest of the course.